Who Paid My Doc
Matthew Logsdon
Hematology & Oncology Colorado Springs, CO Medical Doctor
NPI 1457336976 CMS profile 66223
6031 E Woodmen Rd Ste 200, Colorado Springs, CO 80923
General payments
$11,092
Research payments
$0
Ownership & investment interest
$0
Research they led as principal investigator
$356,834
Through program year 2025, Matthew Logsdon of Colorado Springs, CO is reported in the CMS Open Payments database as having received $11,092 across 31 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $356,834 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 72nd percentile of Hematology & Oncology profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
7 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $164 | 6 | |
| 2024 | General | $9,194 | 4 | |
| 2023 | General | $1,380 | 14 | |
| 2022 | General | $76 | 1 | |
| 2021 | General | $111 | 2 | |
| 2020 | General | $121 | 1 | |
| 2019 | General | $47 | 3 |
Beside peers
- Matthew Logsdon
- Hematology & Oncology median
- Middle half of Hematology & Oncology
- National median
In program year 2025, general payments to Matthew Logsdon were reported at $164. Among 8,769 Hematology & Oncology profiles paid that year, the median was $683 and the middle half received between $143 and $3,154.
Show as a table
| Year | Matthew Logsdon | Hematology & Oncology median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $47 | $529 | $121–$2,516 | $163 |
| 2020 | $121 | $339 | $82–$2,213 | $114 |
| 2021 | $111 | $263 | $49–$1,965 | $132 |
| 2022 | $76 | $416 | $103–$2,395 | $149 |
| 2023 | $1,380 | $542 | $125–$2,646 | $160 |
| 2024 | $9,194 | $692 | $141–$3,008 | $164 |
| 2025 | $164 | $683 | $143–$3,154 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 23 drugsPart D claims
592
Drug cost
$1,698,976
Branded share of claims
36.1%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Ayvakit Avapritinib | Brand | 12 | $439,823 | |
| Brukinsa Zanubrutinib | Brand | 27 | $405,855 | |
| Jakafi Ruxolitinib Phosphate | Brand | 12 | $237,158 | |
| Imbruvica Ibrutinib | Brand | 13 | $187,559 | |
| Tagrisso Osimertinib Mesylate | Brand | 12 | $179,457 | |
| Calquence Acalabrutinib Maleate | Brand | 14 | $134,392 | |
| Eliquis Apixaban | Brand | 60 | $57,646 | |
| Xarelto Rivaroxaban | Brand | 42 | $28,366 | |
| Abiraterone Acetate | Generic | 17 | $22,947 | |
| Anastrozole | Generic | 60 | $1,269 |
The 10 drugs with the highest cost, of 23 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 8,746 Part D prescribers listed as Hematology-Oncology; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 161 billing codesPaid by Medicare
$1,977,179
Medicare patients
500
Services billed
118,123
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 65% | |
| Cancer | 43% | |
| Arthritis | 40% | |
| Chronic kidney disease | 27% | |
| Diabetes | 23% | |
| Ischemic heart disease | 23% | |
| Osteoporosis | 20% | |
| Heart failure | 19% |
| Drug given in the clinic | Where | Patients | Services | Paid by Medicare |
|---|---|---|---|---|
| Injection, pembrolizumab, 1 mg J9271 | Office | 14 | 8,500 | $379,093 |
| Injection, leucovorin calcium, per 50 mg J0640 | Office | 13 | 591 | $2,085 |
| Injection, fosaprepitant, 1 mg J1453 | Office | 28 | 11,850 | $1,309 |
| Injection, gemcitabine hydrochloride, 200 mg J9201 | Office | 11 | 467 | $1,256 |
| Injection, fluorouracil, 500 mg J9190 | Office | 14 | 424 | $950 |
| Injection, palonosetron hcl, 25 mcg J2469 | Office | 42 | 1,130 | $786 |
| Injection, zoledronic acid, 1 mg J3489 | Office | 19 | 152 | $774 |
| Injection, carboplatin, 50 mg J9045 | Office | 12 | 190 | $534 |
| Injection, granisetron hydrochloride, 100 mcg J1626 | Office | 22 | 870 | $214 |
| Injection, dexamethasone sodium phosphate, 1 mg J1100 | Office | 42 | 1,687 | $152 |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
31 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Hematology & Oncology in Colorado
Amy Schmidt
Hematology & Oncology · Denver, CO
Yousuf Gaffar
Hematology & Oncology · Denver, CO
John Burke
Hematology & Oncology · Aurora, CO
Manojkumar Bupathi
Hematology & Oncology · Littleton, CO
Steven Schuster
Hematology & Oncology · Fort Collins, CO
Douglas Reznick
Hematology & Oncology · Aurora, CO
Related records
Hematology & Oncology in Colorado
Practitioners in the same specialty and state, ranked by reported value.
All Hematology & Oncology
Everyone recorded under this specialty, nationwide.
Doctors in Colorado
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.